Eagle Pharmaceuticals Inc.

EGRX03 Oct 2024
Healthcare
$2.78
-0.40 (-39.89%)
Lowest Today
$1.8
Highest Today
$2.8
Today’s Open
$2.78
Prev. Close
$3.56
52 Week High
$14.78
52 Week Low
$1.8
To Invest in Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals Inc.

Healthcare
EGRX03 Oct 2024
-0.40 (-39.89%)
1M
3M
6M
1Y
5Y
Low
$1.8
Day’s Range
High
$2.8
1.8
52 Week Low
$1.8
52-Week Range
52 Week High
$14.78
1.8
1 Day
-
1 Week
-
1 month return
-
3 month return
-45.26%
6 month return
-41.73%
1 Year return
-62.11%
3 Years return
-95.49%
5 Years return
-96.48%
10 Years return
-
Institutional Holdings
Nantahala Capital Management, LLC
30.28
AIGH Capital Management, LLC
9.35
Citigroup Inc
7.73
AQR Capital Management LLC
5.38
Vanguard Group Inc
4.36
Vanguard Total Stock Mkt Idx Inv
2.84
BlackRock Inc
2.72

Market Status

Fundamentals
Market Cap
46.13 mln
PB Ratio
0.18
PE Ratio
4.19
Enterprise Value
102.26 mln
Total Assets
406.16 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Organisation
Eagle Pharmaceuticals Inc.
Employees
134
Industry
Drug Manufacturers - Specialty & Generic
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step